Aprikoksib
Aprikoksib merupakan obat antikanker eksperimental. Aprikoksib digolongkan sebagai inhibitor COX-2 yang digunakan untuk meningkatkan respon pengobatan pada penyakit kanker pankreas.[1] Pengembangan aprikoksib dihentikan pada tahun 2015 dikarenakan hasil uji klinik yang cukup buruk.[2]
![]() | |
|---|---|
| Nama sistematis (IUPAC) | |
| 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide | |
| Data klinis | |
| Kat. kehamilan | ? |
| Status hukum | ? |
| Pengenal | |
| Nomor CAS | 162011-90-7 |
| Kode ATC | ? |
| PubChem | CID 9820073 |
| ChemSpider | 7995822 |
| UNII | 5X5HB3VZ3Z |
| KEGG | D08657 |
| Data kimia | |
| Rumus | C19H20N2O3S |
| SMILES | eMolecules & PubChem |
| |
Referensi
- Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527
. PMID 22829202. - "Apricoxib". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
